2023
Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria
Foy B, Some A, Magalhaes T, Gray L, Rao S, Sougue E, Jackson C, Kittelson J, Slater H, Bousema T, Da O, Coulidiaty A, Colt M, Wade M, Richards K, Some A, Dabire R, Parikh S. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria. JMIR Research Protocols 2023, 12: e41197. PMID: 36939832, PMCID: PMC10132043, DOI: 10.2196/41197.Peer-Reviewed Original ResearchIvermectin mass drug administrationMass drug administrationINTERNATIONAL REGISTERED REPORT IDENTIFIERMalaria incidenceDrug AdministrationMalaria transmissionIntense seasonal malaria transmissionMalaria controlSecondary safety outcomesParallel-group trialSeasonal malaria transmissionAdverse event monitoringActive case surveillancePrimary outcomeControl IINonpregnant individualsPostintervention changesTrial interventionCare interventionsSafety outcomesCluster RandomizedSubset of individualsCase surveillanceConsecutive daysEntomological assessments
2016
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060
Hobbs CV, Gabriel EE, Kamthunzi P, Tegha G, Tauzie J, Petzold E, Barlow-Mosha L, H. BH, Li Y, Ilmet T, Kirmse B, Neal J, Parikh S, Deygoo N, Philippe P, Mofenson L, Prescott W, Chen J, Musoke P, Palumbo P, Duffy PE, Borkowsky W, Team F. Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060. PLOS ONE 2016, 11: e0165140. PMID: 27936233, PMCID: PMC5147802, DOI: 10.1371/journal.pone.0165140.Peer-Reviewed Original ResearchMeSH KeywordsAntimalarialsCD4 Lymphocyte CountChildChild, PreschoolCoinfectionDrug Therapy, CombinationFemaleHIV InfectionsHIV Protease InhibitorsHIV-1HumansInfantLamivudineLopinavirMalaria, FalciparumMalawiMaleNevirapinePlasmodium falciparumReverse Transcriptase InhibitorsRitonavirViral LoadZidovudineConceptsNon-nucleoside reverse transcriptase inhibitorAntiretroviral therapyReverse transcriptase inhibitorBlood smear microscopyHIV protease inhibitorsPositive BSTranscriptase inhibitorProtease inhibitorsClinical malaria incidenceMalaria parasite carriageMalaria-endemic settingsHIV antiretroviral therapyAnti-malarial treatmentLopinavir-ritonavirIllness visitsParasite carriageMalaria treatmentClinical studiesSmear microscopyLower riskMalaria incidenceFurther evaluationMalaria parasitesHIVMonthsTime series analysis of malaria in Afghanistan: using ARIMA models to predict future trends in incidence
Anwar MY, Lewnard JA, Parikh S, Pitzer VE. Time series analysis of malaria in Afghanistan: using ARIMA models to predict future trends in incidence. Malaria Journal 2016, 15: 566. PMID: 27876041, PMCID: PMC5120433, DOI: 10.1186/s12936-016-1602-1.Peer-Reviewed Original ResearchConceptsMalaria incidence